Menu
Evidence based mental health treatment
At St. Mary’s Wellness Center, we offer Spravato (esketamine) treatment, a novel therapeutic option approved for individuals struggling with treatment-resistant depression.
This breakthrough treatment provides new hope for those who have not responded to traditional antidepressant medications.
Spravato, the brand name for esketamine nasal spray, is derived from ketamine and functions as a rapid-acting antidepressant. It is specifically designed for patients with major depressive disorder (MDD) who have tried other antidepressants without success. Spravato is administered under medical supervision in a clinic setting, as it can induce dissociative effects and requires monitoring.
Spravato treatment at St. Mary’s Wellness Center is administered twice a week for the first month, followed by a tapering schedule based on individual response. Each treatment session lasts about two hours, during which the patient self-administers Spravato under the supervision of healthcare professionals. After administration, patients are observed in a comfortable setting to manage any immediate side effects.
Spravato is suitable for adults who:
St. Mary’s Wellness Center is committed to providing innovative mental health treatments.
Our trained professionals have extensive experience in administering Spravato and managing its effects. We ensure a safe, supportive environment for all treatments, prioritizing patient comfort and confidentiality.
Many patients report feeling improvement in their symptoms within the first few weeks of treatment, with some experiencing effects within hours.
Coverage varies, but many insurance plans do cover Spravato treatments for resistant depression. Our staff can help you navigate your insurance benefits.
Common side effects include dissociation, dizziness, nausea, sedation, vertigo, hypoesthesia, anxiety, increased blood pressure, and vomiting. These effects are typically temporary and monitored by our staff.
While both are based on ketamine, Spravato is specifically esketamine and is administered as a nasal spray rather than an IV infusion. It’s also the only form of ketamine approved by the FDA for the treatment of depression.
No, due to its sedative effects, patients are advised not to drive or operate machinery until the next day after a good night’s sleep. Arrangements should be made for transportation home after treatment.
Start Your Journey Towards Mental Health Treatment
